Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) appointed Ryan Koors as Vice President, Investor Relations, effective May 7, 2026. He will report to Executive Vice President and CFO Joseph J. Wolk and succeeds Darren Snellgrove, who is leaving to become CFO of Halozyme. Mr. Koors has 20+ years at Johnson & Johnson and previously served as CFO for Innovative Medicine Global R&D.
Johnson & Johnson (NYSE: JNJ) will present at Bernstein’s 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Management will participate in a Fireside Chat at 11:00 a.m. ET.
A live audio webcast will be available at the company Investor Relations website and an archived replay will be posted; the audio replay is expected approximately 48 hours after the webcast.
Johnson & Johnson (NYSE: JNJ) announced the FDA granted Priority Review to the supplemental BLA for IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA), shortening the U.S. review timeline to approximately six months.
The Priority Review is supported by the Phase 2/3 ENERGY study, in which IMAAVY achieved a durable hemoglobin response and improved fatigue versus placebo; full ENERGY results will be presented at an upcoming medical conference. IMAAVY is not yet approved for wAIHA.
Johnson & Johnson (NYSE: JNJ) reported long-term results for IMAAVY (nipocalimab-aahu) in antibody-positive adults with generalized myasthenia gravis, extending follow-up to 120 weeks. Key findings include sustained symptom improvements, mean MG-ADL reduction of 6.47 points, QMG reduction of 5.97, and durable IgG lowering.
Half of patients reached minimal symptom expression and 32% sustained it for at least 8 weeks; corticosteroid use fell with 57% at low doses. EPIC, a head-to-head study versus efgartigimod, is now enrolling.
Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026.
Management will hold a Fireside Chat at 11:30 a.m. ET. A live audio webcast will be available to investors at www.investor.jnj.com, with an audio replay posted approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) will showcase CARTO innovations at HRS 2026, marking 30 years of the CARTO System and launching the CARTOSOUND SONATA AI module to convert intracardiac echocardiography into detailed maps and auto-label cardiac structures.
The company will present 17 abstracts, new VARIPULSE Platform data, and hands-on demos April 24–2026, highlighting PFA advances and workflow updates across electrophysiology.
Johnson & Johnson (NYSE: JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12, 2026. Management will join a Fireside Chat at 2:20 p.m. ET.
A live audio webcast will be available via Johnson & Johnson’s Investor Relations website with an archived edition available later that day and an audio replay about 48 hours after the webcast.
Johnson & Johnson (NYSE: JNJ) declared a 3.1% quarterly dividend increase, raising the payout from $1.30 to $1.34 per share and marking the 64th consecutive year of annual increases. The new indicated annual dividend is $5.36 versus $5.20 previously.
The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026; the ex-dividend date is May 26, 2026.
Johnson & Johnson (NYSE: JNJ) reported Q1 2026 reported sales of $24.1 billion, up 9.9%, with adjusted Q1 EPS of $2.70 and GAAP diluted EPS of $2.14. The company raised 2026 guidance to estimated reported sales of $100.8 billion (midpoint, +7.0%) and adjusted EPS midpoint of $11.55 (+7.1%).
The quarter included multiple regulatory approvals and launches (ICOTYDE, TECNIS PureSee, TECVAYLI plus DARZALEX FASPRO, VARIPULSE Pro) and an estimated Q1 free cash flow of about $1.5 billion. An Enterprise Business Review is planned for December 8, 2026.
Johnson & Johnson (NYSE: JNJ) presented clinical data April 10, 2026 for the FDA-approved TECNIS PureSee IOL at ASCRS showing strong distance and intermediate vision, high spectacle independence for distance/intermediate, and low bothersome visual symptoms across U.S., Europe and Asia Pacific studies.
Key metrics: a 293-patient real-world study and a 200-patient randomized U.S. trial reported mean binocular uncorrected distance vision ~20/19, spectacle independence up to 96% for distance, and patient satisfaction rates of 93–97%.